Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease-Reference-Cited by-同舟云学术

Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease

Published:2021-06 Issue: Volume:148 Page:69-77
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Lopes Renato D.,Thomas Laine,Di Fusco Manuela,Keshishian Allison,Luo Xuemei,Li Xiaoyan,Masseria Cristina,Friend Keith,Mardekian Jack^ORCID,Pan Xianying,Yuce Huseyin,Jones W. Schuyler

Funder

Pfizer

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference28 articles.

1. REACH registry investigation. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis;Goto;Am Heart J,2008

2. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study;Am Heart J,2002

3. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach;Lip;Chest,2010

4. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke;Marini;Stroke,2005

5. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation;Granger;New Engl J Med,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis;Journal of Managed Care & Specialty Pharmacy;2022-11

2. Trends and Outcomes of Oral Anticoagulation With Direct Current Cardioversion for Atrial Fibrillation/Flutter at an Academic Medical Center;Cardiology Research;2022-04

3. Apixaban lower risk of adverse outcomes, lower cost in non-valvular AF + CAD/PAD;PharmacoEconomics & Outcomes News;2021-03